Heikki Vapaatalo

Prof. Heikki Vapaatalo


Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2017 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Closed access
PDF file
ASAino Siltari
Aino Siltari
HVHeikki Vapaatalo
Heikki Vapaatalo

30 November 2009 in Journal of Nutrition and Metabolism
Verified
Journal Article
Open access
PDF file
TJTiina Jauhiainen
Tiina Jauhiainen
TPTaru Pilvi
Taru Pilvi
Zhongjian ChengZhongjian Cheng
Zhongjian Cheng
HKHannu Kautiainen
Hannu Kautiainen
DMDominik Muller
Dominik Muller
EMEero Mervaala
Eero Mervaala
Tripeptides isoleucyl-prolyl-proline (IPP) and valyl-prolyl-proline (VPP) act as ACE inhibitors in vitro. Double transgenic rats (dTGR) harbouring human renin and human angiotensinogen genes develop malignant hypertension due to increased angiotensin II formation. The present study was aimed to evaluate possible antihypertensive effect of IPP and VPP in this severe model. Four-week-old dTGR were randomized in three groups to receive: (1) water (control), (2) fermented milk containing IPP and VPP, and (3) IPP and VPP dissolved in water for three weeks. Fermented milk, but not peptides in water, attenuated the development of hypertension in dTGR by 19 mmHg versus the control group (P=.023). In vitro vascular function tests showed that high concentrations of the peptides evinced ACE inhibitory properties. In other hypertension related variables, no significant differences between the treatment groups were found. In conclusion, fermented milk product containing IPP and VPP prevents development of malignant hypertension in an animal model.

27 May 2010 in Acta Ophthalmologica
Verified
Journal Article
Closed access
PDF file
AVAnu Vaajanen
Anu Vaajanen
PLPäivi Lakkisto
Päivi Lakkisto
IVIsmo Virtanen
Ismo Virtanen
EKEsko Kankuri
Esko Kankuri
OOOlli Oksala
Olli Oksala
ITIlkka Tikkanen
Ilkka Tikkanen

6 September 2001
Verified
Journal Article
Closed access
HVHeikki Vapaatalo
Heikki Vapaatalo
EME Mervaala
E Mervaala

18 July 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
RLReijo Laatikainen
Reijo Laatikainen
HSHanne Salmenkari
Hanne Salmenkari
TSTimo Sibakov
Timo Sibakov
HVHeikki Vapaatalo
Heikki Vapaatalo
ATAnu Anu Turpeinen Turpeinen
Anu Anu Turpeinen Turpeinen
Unspecific gastrointestinal symptoms associated with milk consumption are common. In addition to lactose, also other components of milk may be involved. We studied whether the partial hydrolysation of milk proteins would affect gastrointestinal symptoms in subjects with functional gastrointestinal disorders. In a randomised, placebo-controlled crossover intervention, subjects (n = 41) were given ordinary or hydrolysed high-protein, lactose-free milkshakes (500 mL, 50 g protein) to be consumed daily for ten days. After a washout period of ten days, the other product was consumed for another ten days. Gastrointestinal symptoms were recorded daily during the study periods, and a validated irritable bowel syndrome-symptom severity scale (IBS-SSS) questionnaire was completed at the beginning of the study and at the end of both study periods. Blood and urine samples were analysed for markers of inflammation, intestinal permeability and immune activation. Both the IBS-SSS score (p = 0.001) and total symptom score reported daily (p = 0.002) were significantly reduced when participants consumed the hydrolysed product. Less bloating was reported during both study periods when compared with the baseline (p < 0.01 for both groups). Flatulence (p = 0.01) and heartburn (p = 0.03) decreased when consuming the hydrolysed product but not when drinking the control product. No significant differences in the levels of inflammatory markers (tumor necrosis factor alpha, TNF-α and interleukin 6, IL-6), intestinal permeability (fatty acid binding protein 2, FABP2) or immune activation (1-methylhistamine) were detected between the treatment periods. The results suggest that the partial hydrolysation of milk proteins (mainly casein) reduces subjective symptoms to some extent in subjects with functional gastrointestinal disorders. The mechanism remains to be resolved.

20 December 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
LTLotta Toivio
Lotta Toivio
HLHanna Launonen
Hanna Launonen
JLJere Lindén
Jere Lindén
MLMarkku Lehto
Markku Lehto
HVHeikki Vapaatalo
Heikki Vapaatalo
RKRiitta A Korpela
Riitta A Korpela
Ketogenic diets (KDs) have been studied in preclinical models of intestinal diseases. However, little is known of how the fat source of these diets influences the intestinal barrier. Herein, we studied the impact of four-week feeding with KD high either in saturated fatty acids (SFA-KD) or polyunsaturated linoleic acid (LA-KD) on paracellular permeability of the intestine to iohexol in healthy male C57BL/6J mice. We investigated jejunal and colonic tight junction protein expression, histological changes, and inflammatory markers (Il1b, Il6, Tnf, and Lcn2), as well as the activity and expression of intestinal alkaline phosphatase (IAP) in feces and jejunal tissue, respectively, and plasma lipopolysaccharide. KDs did not change intestinal permeability to iohexol after two or twenty-six days of feeding regardless of fat quality. SFA-KD, but not LA-KD, upregulated the colonic expression of tight junction proteins claudin-1 and -4, as well as the activity of IAP. Both KDs resulted in increased epithelial vacuolation in jejunum, and this was pronounced in SFA-KD. Jejunal Il1β expression was lower and colonic Il6 expression higher in LA-KD compared to SFA-KD. In colon, Tnf mRNA was increased in LA-KD when compared to controls. Overall, the results suggest that KDs do not influence intestinal permeability to iohexol but elicit changes in colonic tight junction proteins and inflammatory markers in both jejunum and colon. Future research will show whether these changes become of importance upon proinflammatory insults.